| 中文名称 | 8-(2-羟基苯甲酰胺基)辛酸钠 |
| 英文名称 | Salcaprozate Sodium |
| CAS号 | 203787-91-1 |
| 分子式 | C15H22NNaO4 |
| 分子量 | 303.33 |
| EINECS号 | 231-019-4 |
| InChI | InChI=1S/C15H21NO4.Na.H/c17-13-9-6-5-8-12(13)15(20)16-11-7-3-1-2-4-10-14(18)19;;/h5-6,8-9,17H,1-4,7,10-11H2,(H,16,20)(H,18,19);; |
| SMILES | C(C1C=CC=CC=1O)(=O)NCCCCCCCC(=O)O.[NaH] |
| 熔点 | 183 - 185°C |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 形态 | 固体 |
| 颜色 | 白色至类白色 |
| 稳定性 | 吸湿性 |
8-(2-羟基苯甲酰胺基)辛酸钠，简称SNAC，是一种二碳磷酸盐化合物吸收促进剂，用于治疗胃肠道疾病，尤其适用于二碳磷酸盐化合物吸收不良引起的肠胃道疾病。
SNAC (12.5-400 μg/mL; 24 h) has no toxicity to Caco-2 cells, and the survival percentage is above 90% when SNAC is 200 μg/mL.
SNAC (50 and 200 μg/mL) improves the apparent permeability coeffcient (Papp) of RA and SA-B by 2.14-fold and 3.68-fold compared with the Papp of SAs solution.
SNAC improves the oral absorption of both R1 and SAs and enhances bioavailability in rats.
SNAC (2000 mg/kg/d; oral gavage for 13 weeks) related mortality is evident only at the 2000-mg/kg/d level, 20% among males and 50% among females; no clear cause of death is evident.
SNAC (100-1000 mg/kg/d; oral gavage for 13 weeks) induces no mortality in the Wistar rat study at doses up to 1000 mg/kg/d.
| Animal Model: | Sprague-Dawley rats (6-7 weeks) |
| Dosage: | 2000 mg/kg/d |
| Administration: | Oral gavage for 13 weeks |
| Result: | Induced 20% and 50% mortality in males and females at the dose of 2000 mg/kg/d. |